- Home
- DRUG vs OACC Comparison
DRUG vs OACC Comparison
Compare DRUG & OACC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- OACC
- Stock Information
- Founded
- DRUG 2019
- OACC 2024
- Country
- DRUG United States
- OACC United States
- Employees
- DRUG N/A
- OACC N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- OACC
- Sector
- DRUG Health Care
- OACC
- Exchange
- DRUG Nasdaq
- OACC NYSE
- Market Cap
- DRUG 260.6M
- OACC 246.8M
- IPO Year
- DRUG N/A
- OACC 2024
- Fundamental
- Price
- DRUG $39.85
- OACC $9.98
- Analyst Decision
- DRUG Buy
- OACC
- Analyst Count
- DRUG 1
- OACC 0
- Target Price
- DRUG $75.00
- OACC N/A
- AVG Volume (30 Days)
- DRUG 89.2K
- OACC 33.5K
- Earning Date
- DRUG 02-11-2025
- OACC 01-01-0001
- Dividend Yield
- DRUG N/A
- OACC N/A
- EPS Growth
- DRUG N/A
- OACC N/A
- EPS
- DRUG N/A
- OACC N/A
- Revenue
- DRUG N/A
- OACC N/A
- Revenue This Year
- DRUG N/A
- OACC N/A
- Revenue Next Year
- DRUG N/A
- OACC N/A
- P/E Ratio
- DRUG N/A
- OACC N/A
- Revenue Growth
- DRUG N/A
- OACC N/A
- 52 Week Low
- DRUG $0.93
- OACC $9.99
- 52 Week High
- DRUG $79.02
- OACC $10.22
- Technical
- Relative Strength Index (RSI)
- DRUG 51.96
- OACC N/A
- Support Level
- DRUG $34.29
- OACC N/A
- Resistance Level
- DRUG $42.47
- OACC N/A
- Average True Range (ATR)
- DRUG 3.54
- OACC 0.00
- MACD
- DRUG -0.04
- OACC 0.00
- Stochastic Oscillator
- DRUG 61.03
- OACC 0.00
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About OACC OAKTREE ACQUISITION CORP III LIFE S
Oaktree Acquisition Corp III Life Sciences is a blank check company.